Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature

Background: Immune checkpoint inhibitors (ICIs) have shown clinical benefit in many advanced tumors, however, pseudo-progression is a noted phenomenon of ICIs characterized by radiologic enlargement of the tumor burden, followed by regression. How to differentiate pseudo-progression from progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hui, Zhou, Xin, Zhang, Ding, Wang, Guoqiang, Cheng, Xiaochun, Xu, Caihong, Yao, Bin, Pang, Linrong, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399050/
https://www.ncbi.nlm.nih.gov/pubmed/32850889
http://dx.doi.org/10.3389/fmed.2020.00366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399050/
https://www.ncbi.nlm.nih.gov/pubmed/32850889
http://dx.doi.org/10.3389/fmed.2020.00366

Ejemplares similares